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The epidermis expresses a number of connexin (Cx) proteins that are implicated in gap junction-mediated cell
communication. Distinct dominantly inherited mutations in Cx31 cause the skin disease erythrokeratoderma
variabilis (EKV) and hearing loss with or without neuropathy. Functional studies reveal tissue-specific effects
of these Cx31 disease-associated mutations. The Cx31 mutants (R42P)Cx31, (C86S)Cx31 and (G12D)Cx31 are
associated with EKV and the mutant (66delD)Cx31 with peripheral neuropathy and hearing loss, however the
mechanisms of pathogenesis remain to be elucidated. Expression of (R42P)Cx31, (C86S)Cx31 and
(G12D)Cx31 in vitro, but not (WT)Cx31 or (66delD)Cx31, cause elevated levels of cell-type specific cell
death. Previous studies suggest that Cx-associated cell death may be related to abnormal ‘leaky’ hemichan-
nels but we produced direct evidence against that being the major mechanism. Additionally, our immuno-
cytochemistry showed upregulation of components of the unfolded protein response (UPR) in cells
expressing the EKV-associated Cx31 mutants but not (WT)Cx31 or (66delD)Cx31. We conclude that the endo-
plasmic reticulum (ER) stress leading to the UPR is the main mechanism of mutant Cx31-associated cell
death. These results indicate that, in vivo, ER stress may lead to abnormal keratinocyte differentiation and
hyperproliferation in EKV patient skin.
INTRODUCTION
Connexins (Cxs) are the major constituents of gap junctions,
aqueous pores that connect the cytoplasms of two cells and
allow the transfer of ions and small molecules (,1 kDa)
between them. Six Cx proteins assemble to form a con-
nexon/hemichannel, which can traffic to the plasma membrane
and dock with a hemichannel from an adjacent cell to form an
intercellular channel. Hemichannels may also have functional
roles at the plasma membrane including paracrine signalling
(1–3) and the propagation of calcium waves (4). The impor-
tance of gap junction-associated cell communication is indi-
cated by the association of mutations in Cx genes with a
range of inherited human disorders (5–7), mouse models (8)
and expression and/or localization changes in various disease
processes including cancer (9).
The epidermis of skin is predominantly composed of
keratinocytes which undergo differentiation, ultimately
leading to the formation of the stratum corneum to produce
the skin barrier. Cx31 is highly expressed in the stratum gran-
ulosum in the upper differentiating layer of the epidermis
(10,11) and is also found in peripheral nerves and the
cochlea (12). Germline mutations in the GJB3 gene encoding
Cx31 are associated with deafness, neuropathy and skin
disease, indicating that Cx31 has a role in both epidermal
differentiation plus auditory and neuronal function (13).
Multiple autosomal dominant [including (R42P)Cx31,
(C86S)Cx31 and (G12D)Cx31 (14,15)] and recessive
[(L34P)Cx31 (16)] Cx31 mutations are associated with the
skin disease erythrokeratoderma variabilis (EKV), a disorder
characterized by hyperkeratotic plaques with fixed and
transient erythematous patches (17). A dominant neuropathy
mutation, (66delD)Cx31, has also been identified in a family
with sensorineural hearing loss and peripheral neuropathy
(12) and other mutations in Cx31 are associated with non-
syndromic hearing loss (18–20).
To whom correspondence should be addressed. þ44 2078827167; Fax: þ44 2078827172; Email: d.p.kelsell@qmul.ac.uk
# The Author 2009. Published by Oxford University Press.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/
licenses/by-nc/2.5/uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is
properly cited.
Human Molecular Genetics, 2009, Vol. 18, No. 24 4734–4745
doi:10.1093/hmg/ddp436
Advance Access published on September 14, 2009
Previous investigations involving microscopy of EGFP-
tagged Cxs expressed in vitro have shown that the EKV
mutants and the neuropathy mutant have impaired trafficking
to the plasma membrane with a predominantly cytoplasmic
localization in contrast to the wild-type which forms aggre-
gates at the plasma membrane and gap junction-like plaques
(21). Unlike wild-type or (66delD)Cx31, the expression of
the EKV mutants are associated with elevated levels of
in vitro cell death (21–23) through a mechanism which
remains to be elucidated.
Basal activity of Cx hemichannels is low, with the majority
remaining closed most of the time (24), but opening may be
induced by stimuli including low extracellular calcium
(4,25,26). Open hemichannels can release molecules such as
ATP, glutamate and NADþ and lead to uptake of others
(reviewed in 1). Decreased cell viability caused by the
expression of some Cx26 and Cx30 disease-associated
mutants has been attributed to the presence of hemichannels at
the plasma membrane which are ‘leaky’ when cells are incu-
bated in physiological levels of extracellular calcium, with
rescue of the phenotype occurring under high levels of
calcium (3,27,28). It is suggested that this abnormal hemichan-
nel activity can contribute to the disease phenotype in vivo (29).
In contrast, data from another study investigating Cx26 skin and
deafness mutants suggest that aberrant hemichannels are not the
major mechanism of cell death for these mutants (30).
In this investigation, high levels of cell death were still
observed with (R42P)Cx31, (C86S)Cx31 and (G12D)Cx31
when incubated in high extracellular calcium, indicating that
hemichannel-mediated cell death is not the major mechanism
for these mutants. We describe a novel association of the
expression of EKV-associated mutants with upregulation of
components of the unfolded protein response (UPR) in vitro.
Factors that induce endoplasmic reticulum (ER) stress
in cells can lead to the UPR, a cellular process which can
induce signalling pathways to cope with stresses, or if this
fails, to induce cell death (31). Though the precise molecular
mechanism of action of the EKV-associated dominant Cx31
mutations still remains to be elucidated, our data indicate
that these mutants induce ER stress, suggesting for the first
time the major mechanism of the cell death phenotype of
Cx31 skin disease mutants.
RESULTS
Cx31 mutants show defective trafficking and are located on
cytoplasmic membranous structures
(WT)Cx31-EGFP and the mutants (R42P)Cx31-EGFP, (C86S)
Cx31-EGFP and (66delD)Cx31-EGFP [and (G12D)Cx31-
EGFP, data not shown] were expressed in HeLa, NTERT
and SH-SY5Y cells (Fig. 1). The localization of each specific
mutant was comparable in all three cell types. Microscopy
confirmed that (WT)Cx31-EGFP traffics to the cell surface
membrane forming bright aggregates between cells, indicative
of gap junction plaques. In contrast, the four mutants that were
tested appear to mistraffic and have a cytoplasmic distribution.
Cells expressing each of the mutants lack the gap junction-like
aggregates between cells that are found with the wild-type.
(G12D)Cx31-EGFP showed a similar behaviour (data not
shown). These data are in agreement with the previous inves-
tigations performed in HeLa (22,23) and fibroblast and kerati-
nocyte cell lines (21).
Confocal microscopy reveals subtle differences between the
different mutant Cx proteins. The EKV-associated mutants are
located on large bright aggregates (.3 mm in diameter) in the
cytoplasm, in contrast to the neuropathy mutant
(66delD)Cx31-EGFP which has a more diffuse localization,
residing on smaller punctate structures (,2 mm in diameter).
This diffuse punctate localization is distinct from the more
homogenous undefined diffuse pattern of EGFP alone (see
Supplementary Material, Fig. S1), consistent with a soluble
cytosolic protein, suggesting each of the Cx31 mutant proteins
reside on cytoplasmic membranous structures.
Additionally, non-EGFP tagged constructs were used to
confirm that the differences in trafficking of the different
Cx31 proteins was not due to the presence of the EGFP tag
(Supplementary Material, Fig. S2).
To confirm that the majority of the mutant protein does not
form gap junction plaques, sequential detergent-based subcel-
lular fractionation of cell lysates was performed (Fig. 2). This
involved solubilizing crude cell lysate in saponin followed by
Triton X-100 then SDS to assess each protein’s detergent solu-
bility. The Triton-insoluble pool of wild-type Cx31 (indicative
of gap junction plaques) was greatly reduced for
(66delD)Cx31-EGFP protein, which was present mainly in
the Triton-soluble fraction. The absence of saponin-soluble
(cytosolic) Cx protein indicates that all Cx proteins tested
are present on membranous structures. Identical fractionation
of cells expressing skin disease mutants was also performed;
however, the low transfection efficiency of these mutants pre-
vented conclusive results from being obtained (data not
shown). Additionally, a microscopical approach was used to
confirm these results by visualizing any remaining EGFP flu-
orescence after washing out soluble protein in saponin and/or
Triton X-100. This supported (C86S)Cx31-EGFP also being
on membranous structures like the other Cx31 proteins (Sup-
plementary Material, Fig. S3).
Aberrant hemichannel activity is not the main mechanism
for the cell death phenotype associated with the skin
disease mutants
Quantification of cell death by Fluorescence-activated cell
sorting (FACS) analysis based on EGFP fluorescence and
propidium iodide (PI) uptake showed that expression of
(R42P)Cx31-EGFP, (C86S)Cx31-EGFP and (G12D)Cx31-
EGFP leads to decreased cell viability, unlike (WT)Cx31-
EGFP or (66delD)Cx31-EGFP (Fig. 3). This is in agreement
with the previous observations (21,23). There was less death
observed in SH-SY5Y cells compared with HeLa and
NTERT, suggesting cell-type processing of the mutants.
Previous studies involving expression of specific Cx26 or
Cx30 mutants in cell lines/oocytes have suggested that abnor-
mal hemichannels cause cell death due to the observation that
increasing extracellular calcium rescued the cell death pheno-
type (3,27,28). To investigate if aberrant hemichannels lead to
the EKV mutant-induced cell death phenotype, transfected
cells were maintained in physiological or high calcium and
cell death was quantified by FACS analysis of PI uptake
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(dead cells are permeable to PI). There was little effect on cell
viability of SH-SY5Y cells when the extracellular calcium
levels were raised for all of the constructs (Fig. 3, hatched
bars). There was a small reduction in cell death of HeLa and
NTERT cells transfected with (R42P)Cx31-EGFP and
(G12D)Cx31-EGFP, and of HeLa cells transfected with
(C86S)Cx31-EGFP, when maintained in 3.6 mM calcium
compared with those maintained in physiological concen-
trations of calcium.
Despite the trend of a small reduction in cell death observed
when the extracellular calcium concentration was raised,
increases in cell viability did not occur as was reported with
Cx26 and Cx30 mutants (3,27,28). In this investigation, elev-
ated levels of cell death were still observed under high-
extracellular calcium, suggesting that hemichannel-mediated
cell death is not the main mechanism for the Cx31 EKV
mutants. In addition, time-lapse imaging of NEB1 keratino-
cyte cells microinjected with (G12D)Cx31-EGFP and
incubated with the calcium-sensitive indicator dye Calcium
Orange showed that loss of intracellular calcium occurred
only after cell death, indicated by vesicle movement ceasing,
rather than a continuous leaking that would be expected
if abnormal hemichannels were responsible for cell death
(Fig. 4). These data indicate that the major mechanism of
cell death associated with these mutants is not due to abnormal
hemichannel function.
Cx31 EKV mutants colocalize with proteasome markers
Certain Cx32 mutants have been shown to accumulate in the
Golgi apparatus (32) and ER (33). To determine whether the
EKV- or neuropathy-associated Cx31 mutants colocalize
with the Golgi apparatus, ER or other subcellular compart-
ments known to be involved in Cx assembly and trafficking
(reviewed in 34), immunocytochemistry was performed
with subcellular markers specific to the Golgi apparatus, ER,
Figure 1. Distinct subcellular localization patterns are observed upon expression of WT, skin disease- and neuropathy-causing Cx31 in HeLa, NTERT and
SH-SY5Y cells. In HeLa cells (A–D), bright aggregates are observed at cell–cell boundaries in cells expressing (WT)Cx31-EGFP (A) which are indicative
of gap junction plaques. These aggregates are not observed upon overexpression of any mutant, consistent with their inability to traffic properly to the
plasma membrane. Cells expressing either of the skin disease mutants (R42P)Cx31-EGFP (B) or (C86S)Cx31-EGFP (C) display larger brighter aggregates
than cells expressing the neuropathy mutant (66delD)Cx31-EGFP (D), which show protein residing on smaller diffuse punctate structures (distinct from the
diffuse non-punctate EGFP localization (see Supplementary Material, Fig. S1). A similar subcellular localization is observed when the WT and mutant Cx31
constructs are expressed in the immortalized keratinocyte cell line NTERT (E–H) and the neuroblastoma cell line SH-SY5Y (I–L). DAPI-stained nuclei
are shown in blue.
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lysosome and proteasome (Fig. 5) as well as the endosome,
mitochondria and microtubules (data not shown). Although
(66delD)Cx31-EGFP staining looks like it is localized to
the ER, we did not find any co-localization with any of the
ER marker proteins tested [calnexin (Fig. 5), BiP/GRP78
(Fig. 6), KDEL nor GRP94 (data not shown)]. In addition,
there was little or no colocalization with the ER and the
EKV mutants. Similarly, there was no colocalization of
either wild-type or mutant Cx31 protein with the majority of
the other subcellular markers tested, indicating that the
major pool of each of the mistrafficked mutants does not
reside in any of these compartments. The proteasome
marker, however, was upregulated in cells expressing the
EKV-associated mutants (R42P)Cx31-EGFP and
(C86S)Cx31-EGFP with colocalization observed, but not in
cells expressing the wild-type or neuropathy-associated
mutant (66delD)Cx31-EGFP (Fig. 5).
Overexpression of skin disease mutants cause upregulation
of components of the UPR in vitro
However, similar to the proteasome marker, there was an upre-
gulation of both BiP/GRP78 and proteins containing the KDEL
motif in HeLa cells expressing the EKV mutants. The KDEL
amino acid motif is present at the C terminus of ER resident
proteins including the ER chaperone BiP/GRP78. BiP/GRP78
was also found to be upregulated in cells expressing
(R42P)Cx31-EGFP and (C86S)Cx31-EGFP but not the wild-
type or neuropathy-associated mutant (66delD)Cx31-EGFP
(Fig. 6). Furthermore the dramatic upregulation of BiP/GRP78
is specific to those cell lines where the most cell death is
observed [HeLa (Fig. 6) and NTERT (Fig. 7)].
BiP/GRP78 is a component of the UPR, which can be
induced by ER stress, and may lead to cell death if the
stress is not alleviated (reviewed in 31). For example the neu-
rotoxin 6-OHDA can trigger ER stress inducing the upregula-
tion of UPR markers such as BiP/GRP78 in a dopaminergic
cell line (35). To determine whether the expression of
EKV-associated mutants affect other components of the
UPR as well as BiP/GRP78, immunocytochemistry was
performed which showed that ATF6 and the transcription
factor CHOP/GAAD153 (Fig. 8) as well as XBP1 (data not
shown) were upregulated in HeLa cells expressing the
EKV-associated mutant (C86S)Cx31-EGFP but not
(WT)Cx31-EGFP. Upon ER stress, ATF6 is cleaved and the
N-terminal portion is translocated to the nucleus to initiate
transcription of UPR proteins such as ER chaperones and
ER-associated degradation components (31,36). An increase
in nuclear localization of ATF6 is observed in cells expressing
either (C86S)Cx31-EGFP or (R42P)Cx31-EGFP but not
(WT)Cx31-EGFP or (66delD)Cx31-EGFP (Fig. 8). Addition-
ally, non-EGFP-tagged constructs were used to confirm
that the upregulation/nuclear translocation of BiP/GRP78
and ATF6 was not due to the presence of the EGFP tag
(Supplementary Material, Fig. S2). These results demonstrate
an association of cell death upon expression of the EKV-
associated mutants with UPR components.
DISCUSSION
Cx31 mutants have cytoplasmic localizations
Previous investigations using EGFP-tagged constructs have
shown by microscopy that EKV-associated Cx31 mutants
have a predominantly cytoplasmic localization and their
expression in vitro decreases cell viability, the mechanism of
which was unknown (21,23). However, the neuropathy-
associated (66delD)Cx31 also mistraffics but does not increase
cell death (21,23). Our data confirm and extend this obser-
vation. Confocal microscopy in three different cell lines
revealed that the skin disease mutants are characterized by
bright cytoplasmic aggregates (.3 mm in diameter) and the
neuropathy mutant by smaller punctate structures (,2 mm in
diameter), whereas subcellular fractionation demonstrates
that both classes are membrane bound. This led us to hypoth-
esise that this difference in intracellular localization could give
an indication as to why the two classes of mutants cause
different diseases and in vitro cell phenotypes.
The G12S and E208K Cx32 mutants, both linked to
X-linked Charcot-Marie-Tooth disease (CMTX), have been
found to colocalize with the Golgi apparatus (32) and the
ER (33), respectively. We have excluded similar backing-up
of mutant Cx31 protein in a range of intermediate transport
organelles as well as accumulation in the lysosome. The skin
disease mutants were detected in the proteasome, known
to be involved in the degradation steps of the turn-over
cycle of Cx protein (6,34). In addition, we observed an
upregulation of proteasome markers as well as proteins
containing the ER resident motif KDEL and the ER chaperone
BiP/GRP78.
Figure 2. The Cx31 mutant 66delD is saponin-insoluble and Triton-soluble,
indicating membranous localization. Sequential detergent solubilization of
crude lysate of HeLa cells overexpressing (WT)- and (66delD)Cx31-EGFP
in saponin followed by Triton X-100 then SDS revealed no Cx31 protein is
saponin-soluble which would be indicative of a cytosolic pool (in contrast
to the unfused EGFP protein). The presence of (66delD)Cx31-EGFP protein
solely in the Triton-soluble fraction indicates that the protein is mainly
present on membranous structures. The additional presence of a
Triton-insoluble pool of (WT)Cx31-EGFP (present in the SDS-soluble frac-
tion) is indicative of gap junction aggregates. The LAMP1 and GAPDH
control proteins are present in the Triton- and saponin-soluble fractions,
respectively, as expected.
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Aberrant hemichannels are not the main mechanism of
EKV-associated mutant cell death
ATP has been hypothesised as a paracrine signalling molecule
(1–3). Furthermore, it has been suggested that deregulated
release of ATP and other molecules could disrupt paracrine
signalling within the skin affecting keratinocyte differentiation
and leading to hyperproliferation (3,27–29). The cell death
phenotype linked to the expression of hidrotic ectodermal dys-
plasia Cx30 mutants, G11R and A88V, has been attributed to
aberrant hemichannel activity at the plasma membrane of
oocytes maintained in low levels of extracellular calcium
(3). A similar mechanism has been attributed to expression
of keratitis-ichthyosis-deafness syndrome-associated Cx26
mutants G45E and D50N in oocytes (28). Cell death could
be rescued by raising the levels of extracellular calcium to
close any hemichannels at the cell surface (28). However,
another study could not reproduce these findings with
(D50N)Cx26-EGFP expression in human cell lines (30),
suggesting that other mechanisms may account for a pro-
portion of the observed in vitro human cell death attributable
to some Cx mutants.
Quantification of cell death in HeLa cells expressing
(R42P)Cx31-EGFP, (C86S)Cx31-EGFP and (G12D)Cx31-
EGFP showed that although there was generally some reduction
when the calcium levels were raised, levels of cell death still
remained high. Time-lapse imaging of keratinocytes microin-
jected with (G12D)Cx31-EGFP and an indicator dye, Calcium
Orange, showed that loss of intracellular calcium occurred
only after cell death, indicated by vesicle movement ceasing,
rather than a continuous leaking that would be expected if abnor-
mal hemichannels were responsible for cell death. Although we
do not exclude the possibility that some hemichannels reach the
plasma membrane and exhibit aberrant activity, these data
indicate that hemichannel-mediated cell death is not the main
mechanism underlying the in vitro cell death phenotype.
Overexpression of the EKV mutants in vitro leads
to upregulation of components of the UPR
The accumulation of unfolded proteins in the ER can induce
ER stress leading to activation of the UPR pathway, a
process which has been linked to the pathogenesis of a
variety of disorders including heart disease, neurological dis-
eases such as Alzheimer’s disease, diabetes and cancer
(reviewed in 31). ER stresses including disrupted redox
regulation, glucose deprivation, viral infection, inclusion
body diseases and high fat diet can lead to the induction of
the UPR, with the objective of restoring normal ER function
(31). In mammals, the ER chaperone BiP/GRP78 is bound
to inositol-requiring kinase (IRE1a), PERK (PRKR-like ER
kinase) and ATF6 (activating transcription factor), however
when unfolded proteins accumulate in the ER, these trans-
membrane ER proteins are activated, signalling through
pathways which can lead to the reduction of protein translation
and increased the expression of ER chaperone proteins. If
these mechanisms fail to control the stress, pathways leading
to cell death are activated (31). The UPR has been shown to
be activated during normal epidermal keratinocyte differen-
tiation (37), thus deregulated UPR activity may lead to
keratinocyte hyperproliferation.
In this study, we have shown that the in vitro expression of
(R42P)Cx31-EGFP and (C86S)Cx31-EGFP but not wild-type
nor (66delD)Cx31-EGFP was found to correlate with upregu-
lation of the ER resident chaperone BiP/GRP78 and other
components of the UPR including ATF6, XBP1 and CHOP/
GAAD153. This is the first report of an association of
expression of Cx mutants with induction of the UPR, and
although members of the UPR have been previously linked
with psoriasis and Bowen’s disease (37), this is the first
study to link EKV with the UPR. There is one report of a
recessive Cx mutant that did not appear to cause the nuclear
translocation of CHOP/GAAD153 (38), but our study shows
Figure 3. FACS quantification of cell death phenotype. Quantification of cell death by FACS showed that the expression of (R42P)Cx31-EGFP,
(C86S)Cx31-EGFP and (G12D)Cx31-EGFP leads to decreased cell viability, unlike (WT)Cx31-EGFP or (66delD)Cx31-EGFP. There is less death of
SH-SY5Y cells compared with HeLa and NTERT, suggesting cell-type processing of the mutants. Increasing the calcium concentration to 3.6 mM decreased
the amount of cell death in some of the samples, however complete rescue was not observed, suggesting that aberrant hemichannels are not the predominant
mechanism of cell death for these mutants. Error bars represent SEM.
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that dominant Cx31 mutations associated with increased cell
death do upregulate this protein.
It has been hypothesised that Cx mutants lead to pathogen-
esis by causing defective gap junction formation/regulation,
by disrupting other Cxs in the cell, forming aberrant
hemichannels or having an abnormal conformational structure
(6,39). Our in vitro findings demonstrate that the expression of
the skin disease mutants leads to the misregulation of the
UPR and that ER homeostasis cannot be restored, leading to
elevated levels of cell death. The EKV mutants’ location
within the cytoplasm could lead to ER stress, as could the
incorrect folding of the protein when transported through
the ER. Incorrect protein folding has been implicated in the
pathogenesis of Cx32 mutants causing CMTX (40).
Figure 4. Calcium Orange does not leave the cells expressing EKV-associated Cx31, while they are undergoing cell death, eliminating a hemichannel mech-
anism. Examples of images from time-lapse recording of keratinocytes expressing (G12D)Cx31-EGFP. Although EGFP was also recorded, only phase contrast
and Calcium Orange images are presented. Time after microinjection is indicated. Cells were loaded with Calcium Orange 30 min after microinjection and
recording started 50 min after microinjection. The cell in the centre of the field died 81 min after microinjection and lost calcium 85 min after microinjection.
Scale bars are 10 mm.
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Figure 5. Proteasome markers are upregulated in cells expressing the skin disease mutants and colocalize with the mistrafficked protein. Colocalization studies
with the EKV- and neuropathy-associated Cx31 mutants and markers against subcellular compartments known to be involved in connexin assembly and traffick-
ing including the Golgi apparatus (A–D), lysosome (E–H) and the ER (I–L) indicates that the major pool of each of the mistrafficked mutants does not reside in
any of these compartments. In contrast, the proteasome marker (Q–T) is upregulated in cells overexpressing the (R42P)Cx31-EGFP (N) and (C86S)Cx31-EGFP
(O) mutant, and a degree of colocalization is observed (shown in yellow in V and W). This is not observed in cells overexpressing (WT)Cx31-EGFP (M) or
(66delD)Cx31-EGFP (P). EGFP-tagged connexin protein is shown in green. The subcellular marker antibody staining is shown in red. DAPI- stained nuclei are
shown in blue.
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Cell death has been linked with in vivo Cx phenotypes par-
ticularly certain Cx26 deafness mutations. Cell death is
observed in the epithelia supporting the hair cells within the
organ of Corti in mice with cell-type specific deletion of
Cx26 (41) and, in contrast, delayed cell death is observed in
keratinocytes expressing recessive hearing loss-associated
Cx26 mutation (42–44). It is not known whether the cell
death observed with the Cx31 EKV mutants in vitro also
occurs in vivo, and, if so, how this increased level of cell
death relates to the disease pathogenesis of EKV. However,
abnormal gap junction communication and/or cell death
during keratinocyte differentiation has been suggested to
lead to hyperproliferation (reviewed in 39) and disease.
In this study, we have elucidated a novel mechanism linking
expression of the EKV-associated mutants of Cx31 to the in
vitro cell death phenotype by demonstrating an upregulation
of the UPR, revealing ER stress as the major mechanism.
Furthermore, we have suggested that the cell death phenotype
caused by expression of the EKV-associated mutants could
explain the in vivo skin disease phenotype by leading to the
hyperproliferation that is characteristic of this disease.
MATERIALS AND METHODS
Cells lines, constructs and transfection
HeLa and SH-SY5Y cells were obtained from the American
Type Culture Collection. NEB1 and NTERT cells lines were
generated as described elsewhere (42,45). All EGFP-tagged
DNA constructs were generated as described previously
(21). Non-EGFP-tagged Cx31 constructs were generated by
excising the EGFP cDNA with XmaI and NotI and replacing
it with a duplexed oligo insert containing an in-frame stop
codon (sense¼CCGGACTAGTCA, antisense¼GGCCTGA
CTAGT). Cells were transiently transfected using Fugene6
(Roche) using the manufacturer’s instructions. The percentage
of cells expressing the EGFP constructs after 48 h is shown in
Supplementary Material, Figure S4.
Antibodies
All antibodies used are available commercially. Antibodies
against Calnexin, LAMP1 and GM130 were purchased from
BD Biosciences, the Cx31 antibody was purchased from
Abnova and antibodies against ATF6, CHOP/GAAD153,
GFP, GRP94, KDEL, Proteasome 20s, alpha-tubulin and
XBP1 were purchased from Abcam. The GM130 and Protea-
some 20s results were confirmed using an anti-giantin anti-
body (Covance) and an anti-58K protein antibody (Abcam),
and an anti-ECM29 antibody (Abcam), respectively (data
not shown). The BiP/GRP78 antibody (raised against the N-
terminal) was purchased from Sigma (Dorset, UK), and
results were confirmed using a C-terminal specific antibody
purchased from Sigma and a second C-terminal specific anti-
body purchased from BD Bioscience (data not shown).
Fluorescent cytochemistry
Cells were seeded onto coverslips the day after transfection,
and 24 h later fixed in 4% paraformaldehyde for 30 min.
Cells were mounted in Immu-mount (Shandon Thermo, UK)
containing 50 ng/ml DAPI. For immunocytochemistry, cells
were permeabilized after fixation in 0.1% Triton X-100 for
Figure 6. Expression of Cx31 skin disease mutants disrupts the ER marker BiP/GRP78. The ER marker BiP/GRP78 (E–H) is upregulated/disrupted in HeLa
cells overexpressing (R42P)Cx31-EGFP (B) and (C86S)Cx31-EGFP (C) but not (WT)Cx31-EGFP (A) or (66delD)Cx31-EGFP (D). Note the exposure settings
have been optimized for each field of view, the surrounding non-transfected control cells in (F and G) have a similar level of BiP/GRP78 expression as the cells
in (E and H). The KDEL antibody also shows a marked upregulation in cells expressing the (R42P)Cx31-EGFP and (C86S)Cx31-EGFP construct (data not
shown). The DAPI-stained nuclei are shown in blue.
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10 min, blocked in 3% bovine serum albumin (BSA) for
15 min and incubated for 1 h with primary antibody diluted
1/50 (KDEL), 1/100 (LAMP1, GM130, BiP/GRP78), 1/200
(ATF6, Calnexin, CHOP/GAAD153, XBP1) or 1/1000 (alpha-
tubulin) in 3% BSA. Cells were washed in PBS, incubated for
1 h with the appropriate Alexa Fluor 488 or Alexa Fluor 546
secondary antibody (Invitrogen) diluted 1/1000 in PBS,
before being washed in PBS and mounted as described
above. Cells were visualized using a Zeiss META 510 confo-
cal microscope and manipulated using LSM Image Browser
and Adobe Photoshop. The exposure settings were optimized
for each field of view to illustrate subcellular localization. In
the case of upregulation of cellular markers, the unchanged
levels of protein in surrounding non-transfected control cells
were used for cross-panel comparisons.
Fluorescence-activated cell sorting
Cells were seeded at 30–40% confluency in six-well plates
and transfected as described above. Six hours post-transfection
Figure 7. Expression of either Cx31 skin disease mutant also disrupts the ER marker BiP/GRP78 in NTERT cells but not SH-SY5Y cells. The ER marker BiP/
GRP78 (E–H) is upregulated/disrupted in NTERT cells expressing (R42P)Cx31-EGFP (B) and (C86S)Cx31-EGFP (C) but not the (WT)Cx31-EGFP (A) or
(66delD)Cx31-EGFP (D). In contrast, BiP/GRP78 (M–P) is unaffected by the expression of any Cx31-EGFP construct (I–L) in SH-SY5Y cells. The
DAPI-stained nuclei are shown in blue.
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cells were either maintained in media containing physiological
levels of calcium (1.05 mM for SH-SY5Y and NTERT, 1.8 mM
for HeLa) or calcium chloride was added to raise the extra-
cellular calcium levels to 3.6 mM. Twenty-four hours post-
transfection, adherent cells were trypsinized and pelleted and
combined with pelleted non-adherent (dead) cells. Cells
were resuspended in ice-cold PBS/1% FCS and stained with
1 mg/ml PI 5 min prior to cell sorting. Samples were analysed
on a BD LSRII and the percentage of EGFP-positive (trans-
fected) cells that were PI positive (dead) was calculated.
Time-lapse imaging of cell death and calcium
concentration
NEB1 keratinocytes were seeded into 35 mm glass-bottom
dishes, and 2 days later 20 cells in an isolated colony
were microinjected using an Eppendorf Transjector and micro-
manipulator with 0.05 mg/ml of (G12D)Cx31-EGFP cDNA
construct. After microinjection, cells were incubated in
Calcium Orange loading medium [2 mmol Calcium Orange
(Molecular Probes) and 0.02% w/v Pluronic F-127 (Molecular
Figure 8. Expression of the Cx31 skin disease mutants upregulate components of the UPR pathway. The UPR components ATF6 (E–H) and CHOP/GAAD153
(M–P) are upregulated in HeLa cells overexpressing (R42P)Cx31-EGFP (B and J) and (C86S)Cx31-EGFP (C and K) but not the (WT)Cx31-EGFP (A and I) nor
the (66delD)Cx31-EGFP neuropathy mutant (D and L). Furthermore, the ATF6 staining (F and G) has a more nuclear localization in cells expressing
(R42P)Cx31-EGFP (B) and (C86S)Cx31-EGFP (C) compared with untransfected cells and cells expressing (WT)Cx31-EGFP (A) and (66delD)Cx31-EGFP
(D), indicating that the cleaved N-terminal portion has been translocated to the nucleus. The DAPI-stained nuclei are shown in blue.
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Probes)] for 30 min, then normal culture medium for 20 min,
before being imaged on an Axiovert 135 TV microscope
(Carl Zeiss Ltd.). Acquired sequences were analysed in the
AQM6 software by determining time points of cell death
defined as cessation of active subcellular vesicle movement,
and time points of calcium loss defined as the first dramatic
reduction of integrated intracellular fluorescence intensity of
Calcium Orange in comparison to uninjected cells.
Detergent fractionation
HeLa cells were transfected as described above and seeded
into 90 mm dishes 24 h later; and 48 h post-transfection,
cells were washed in ice-cold PBS and scraped into 1 ml
ice-cold saponin buffer [0.01% saponin in 10 mM Tris
pH7.5, 140 mM NaCl, 5 mM EDTA, 2 mM EGTA plus com-
plete protease inhibitor cocktail (Roche)]. Cells were disrupted
with a 21G needle, then centrifuged at 16 000g for 30 min at
48C. The supernatant was mixed with SDS–PAGE loading
buffer (final component concentrations: 100 mM Tris pH 6.8,
4% SDS, 20% glycerol, 0.005% Bromophenol Blue and
2.5% b-mercaptoethanol) and boiled for 5 min, while the
pellet was resuspended in ice-cold Triton buffer (1% Triton
X-100, other buffer components as saponin buffer), disrupted
with a needle and repelleted at 16 000g for 30 min at 48C. The
supernatant was again boiled in SDS loading buffer, while the
pellet was solubilized in SDS–PAGE loading buffer by soni-
cating and boiling. All fractions were analysed by western
blotting using standard procedures.
The different solubilities of (WT)Cx31-EGFP and the
mutants were verified directly by immunofluorescence.
Three low-power fields of view were taken of a near-confluent
monolayer of HeLa cells expressing each Cx31 construct after
being subjected to either saponin extraction or triton extrac-
tion. Buffer components were as above except Triton X-100
was used at 0.1%. Saponin-treated cells were washed for
1 min three times, and Triton X-100-treated cells were
washed once for 1 min. The number of green transfected
cells were counted in each field of view, and compared with
the number of cells in a field that had no detergent treatment.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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